Skip to main content
Steven Feldman on Muck Rack

Steven Feldman

Tampa
As seen in: Nature, WebMD, Wiley Online Library, British Pharmacological Society, ScienceDirect, Frontiers, MDPI, Taylor & Francis Online, Expert Review of Anticancer Therapy, JAMA (The Journal of the American Medical Association) and
Public Relations Exec ~ Current Union for Reform Judaism, former CBS, Hallmark Channel. traveler, gym goer, bourbon drinker, happy dad, sad NY Giants fan

Get in touch with Steven

Contact Steven, search articles and posts on X, monitor coverage, and track replies from one place.

Learn more about Muck Rack

Actions

Share this page

Articles

Can AI Cut Your Psoriasis Admin Hours in Half?

|
By Steven Feldman, Faranak Kamangar
| Medscape Verified
Episode Transcript This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Steven Feldman, MD, PhD: Our guest is a board-certified dermatologist and chair of the dermatology department at the Palo Alto Medical Foundation, as well as chair of the San Francisco Dermatological Society, one of the oldest dermatology societies in the country. Our guest’s perspective is unique.
Open in Who Shared Issue with article?

How Confident Should We Be in Psoriasis Biosimilars?

|
By Steven Feldman, Jonathan Kay Verified
| Medscape Verified
Episode Transcript This transcript has been edited for clarity. For more episodes, download the Medscape app or subscribe to the podcast on Apple Podcasts, Spotify, or your preferred podcast provider. Steven R. Feldman, MD, PhD: Hi I'm Dr Steven Feldman. Welcome to the Medscape InDiscussion podcast series on psoriasis. This is episode 4 of our season 4.
Open in Who Shared Issue with article?

Three-Year Patient-Reported Outcomes From Bimekizumab for Plaque Psoriasis: The BE RADIANT Randomized Clinical Trial With Open-Label Extension

|
By Matthias Augustin, Steven Feldman, Richard Warren
| Dialnet - Universidad de La Rioja
Importance Patient-reported outcome (PRO) assessments alongside clinical parameters help to holistically determine treatment benefits. Objective To assess PROs among bimekizumab-treated patients with moderate to severe plaque psoriasis. Design, Setting, and Participants The BE RADIANT multicenter, phase 3b randomized clinical trial and open-label extension (OLE) had a 48-week double-blinded period and 96-week OLE (3 years’ total treatment). Patients initially received bimekizumab or secukinumab.
Open in Who Shared Issue with article?
See all 206 licensed articles (207 Total)